- Conditions
- Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 220
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian Carcinosarcoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
- Biological · Procedure · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 690
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 462 more
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
- Interventions
- Bevacizumab, Irinotecan Sucrosofate
- Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
- Interventions
- Bevacizumab, Everolimus, Octreotide Acetate
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 388
- States / cities
- Mobile, Alabama • Anaheim, California • Antioch, California + 272 more
- Conditions
- Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
- Interventions
- Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 872
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more
- Conditions
- Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
- Interventions
- LFG316, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
- Conditions
- Intraocular Inflammation, Suspected Endophthalmitis
- Interventions
- Non Applicable
- Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
- Conditions
- Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Atezolizumab, Bevacizumab, Capecitabine, Laboratory Biomarker Analysis, Placebo
- Drug · Biological · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more
- Conditions
- Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Capecitabine, Gemcitabine, Bevacizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Pembrolizumab
- Biological · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 23
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 18 more
- Conditions
- Diabetic Macular Edema
- Interventions
- 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 90
- States / cities
- Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
- Interventions
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 163
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
- Interventions
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Pasadena, California • Aurora, Colorado + 13 more
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Physician-guided diagnostic
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
- Interventions
- Bevacizumab, Carboplatin, Ixabepilone, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 230
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more
- Conditions
- Melanoma, Skin Neoplasms
- Interventions
- Axitinib [AG-013736]
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 11
- States / cities
- Orange, California • Miami Beach, Florida • Boston, Massachusetts + 5 more
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
- Interventions
- Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 847 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 72
- States / cities
- Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Drug
- Lead sponsor
- Maturi, Raj K., M.D., P.C.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Anetumab Ravtansine, Bevacizumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 22
- States / cities
- Orange, California • Aurora, Colorado • Coral Gables, Florida + 19 more
- Conditions
- Irvine-Gass Syndrome
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
- Drug · Radiation
- Lead sponsor
- Amer Zureikat
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
- Interventions
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 541
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more
- Conditions
- Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Interventions
- BNT323, BNT327
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 19 more